# A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

> **NCT00542386** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 642 (actual)

## Conditions studied

- Chronic Kidney Disease
- Dialysis
- Hyperphosphatemia
- Dyslipidemia

## Interventions

- **DRUG:** MCI-196
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00542386
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 642 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542386, "A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00542386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*